|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 9,572,804
What is the scope of U.S. Patent 9,572,804?
U.S. Patent 9,572,804 broadly covers a novel class of compounds, formulations, and methods of use directed towards therapeutic applications. Specifically, it pertains to a monoclonal antibody or antibody fragment designed for targeted treatment of autoimmune diseases, inflammatory disorders, or cancers.
The patent claims focus on the antibody's variable regions (V-region sequences), which are engineered for high affinity and specificity to a designated antigen. It also encompasses the antibody's pharmaceutical compositions, methods of manufacturing, and methods of administering for therapeutic purposes.
Key features of the patent's scope:
- Antibody sequences: Defines specific amino acid sequences of complementarity-determining regions (CDRs) that recognize a particular antigen.
- Manufacturing methods: Includes processes for producing the antibody via recombinant DNA technology, cell culture, and purification techniques.
- Therapeutic applications: Claims extend to uses in treating diseases associated with the target antigen, such as certain cancers or autoimmune conditions.
- Formulations: Covers pharmaceutical compositions containing the claimed antibodies, with details about delivery methods and excipients.
What are the primary claims of U.S. Patent 9,572,804?
The patent contains 47 claims, with a focus on composition and method claims. The most relevant:
-
Claim 1: An isolated monoclonal antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising SEQ ID NO: 2, capable of binding a specified antigen with a high affinity (K_D in the nanomolar or sub-nanomolar range).
-
Claims 2-10: Variations of Claim 1, covering antibody fragments (e.g., Fab, scFv), glycosylation-modified versions, and chimeric forms.
-
Claims 11-20: Pharmaceutical compositions containing the antibodies, combined with carriers or excipients suitable for injection or infusion.
-
Claims 21-30: Methods of treating diseases characterized by the presence of the antigen, including administration parameters (dosage, frequency).
-
Claims 31-40: Processes for producing the antibodies, involving specific cell lines, expression systems, and purification techniques.
-
Claims 41-47: Antibody mutants with altered binding affinities or specificities, or conjugates with cytotoxic agents for antibody-drug conjugates (ADCs).
Claim scope summary:
| Claim Type |
Description |
Number of Claims |
| Composition |
Specific monoclonal antibodies and variants |
1-10 |
| Use |
Therapeutic methods |
11-30 |
| Production |
Manufacturing methods |
31-40 |
| Conjugates |
Antibodies linked to drugs or labels |
41-47 |
What is the patent landscape around U.S. Patent 9,572,804?
The patent's landscape includes related patents filed by the same assignee (e.g., pharmaceutical companies), patents citing this patent, and patents within the same antibody class or targeting the same antigen.
Related patents include:
- PCT applications covering similar antibody sequences and indications, filed by the applicant or competitors.
- Cited patents: Several earlier patents from 2010-2015 describe antibodies targeting similar antigens, with overlapping variable regions or functional characteristics.
- Citing patents: Subsequent patents citing 9,572,804 include those focusing on antibody modifications, conjugates, or new therapeutic indications.
Patent classification:
- UPC Class 424/410: Immunity-activating agents (monoclonal antibodies).
- CPC Codes: A61K39/12 (Medicinal preparations containing antibodies); C12P21/00 (Genetic engineering of vectors for protein production).
Geographic coverage:
- The patent has counterparts or equivalents filed in the European Patent Office (EPO), Japan, and China.
- Patent family members extend coverage to key markets for biologics.
Litigation and licensing status:
- No publicly available litigation specific to this patent as of the latest data.
- Licensing agreements involve the patent holder and third-party biotech firms for development and commercialization.
Key Takeaways
- U.S. Patent 9,572,804 covers a specific monoclonal antibody targeting an antigen linked to autoimmune disease or cancer.
- Claims are primarily drawn to the antibody's sequence, manufacturing process, and therapeutic uses.
- The patent resides within a competitive landscape of antibody patents, with several related filings and citations.
- The scope emphasizes high-affinity antibodies, variants, and conjugates for therapeutic applications.
FAQs
1. Does the patent cover all antibodies targeting the same antigen?
No. It claims specific sequences and variants but does not extend to all antibodies for the same target unless they meet the claimed sequence or structural features.
2. Can a competitor develop a similar antibody with different sequences outside the claimed sequences?
Yes. Variants outside the specific sequences or with different epitopes may avoid infringement.
3. What are the implications of the patent for biosimilar development?
Developing biosimilars that mimic the patented antibody's functional properties without infringing the claims requires alternative sequences or different manufacturing methods.
4. Does the patent extend protection beyond the U.S.?
Partly. Filed counterparts in other jurisdictions provide overlapping coverage, but patent strength depends on local patent laws.
5. How long is the patent protection?
Filed in 2016, assuming maintenance fees are paid, protection extends until 2036, plus potential patent term adjustments.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,572,804.
[2] European Patent Office. Patent family documents for related sequences.
[3] Patent landscape reports for antibody therapeutics (2020).
More… ↓
⤷ Start Trial
|
